Storys zum Thema Pharmakologie

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Norgine GmbH

Norgine Announces Appointment of New CEO Janneke van der Kamp

London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Sysmex Europe SE

2

Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.

Fördergesellschaft IZB mbH

2

Record financing rounds at the Munich biotech hub

STADA Arzneimittel AG

Press release: STADA continues strong growth journey in the first half of 2024

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...

Grünenthal Group

2

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients

Gerresheimer AG

10

Gerresheimer: New pictures available

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Fraunhofer-Institut für Produktionstechnologie IPT

Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems

STADA Arzneimittel AG

2

Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals

RHEACELL GmbH und Co. KG

RHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected

Medias Klinikum GmbH & Co KG

The Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre

Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...

eleva GmbH

Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development

Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...

Adragos Pharma

Successful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece

Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...

Adragos Pharma

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories

Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...

Medias Klinikum GmbH & Co KG

The world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission

Technische Universität München

Nanoswitches for tumor targeting

TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...

benfovir AG

benfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)

Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...

benfovir AG

benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS

Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...

Technische Universität München

Overcoming resistance of pancreatic cancer to immunotherapies

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...

Sysmex Inostics GmbH

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...

benfovir AG

New therapeutic approach against SARS-CoV-2 successfully tested

Pfungstadt (ots) - - Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARS-CoV-2 virus in human cells. - The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells. - Preclinical testing of this compound has ...